Anebulo Pharmaceuticals, Inc. (ANEB)
0.3574
-0.03
(-8.36%)
USD |
OTCM |
Sep 09, 16:00
Anebulo Pharmaceuticals Net Income (Quarterly) : -1.999M for Dec. 31, 2025
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2025 | -1.999M |
| September 30, 2025 | -2.158M |
| June 30, 2025 | -2.145M |
| March 31, 2025 | -1.676M |
| December 31, 2024 | -2.463M |
| September 30, 2024 | -2.201M |
| June 30, 2024 | -1.35M |
| March 31, 2024 | -1.654M |
| December 31, 2023 | -2.717M |
| September 30, 2023 | -2.481M |
| June 30, 2023 | -2.496M |
| Date | Value |
|---|---|
| March 31, 2023 | -2.798M |
| December 31, 2022 | -3.827M |
| September 30, 2022 | -2.612M |
| June 30, 2022 | -2.323M |
| March 31, 2022 | -1.876M |
| December 31, 2021 | -1.073M |
| September 30, 2021 | -1.553M |
| June 30, 2021 | -29.11M |
| March 31, 2021 | -0.5558M |
| June 30, 2020 | -0.1746M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
| Johnson & Johnson | 5.534B |
| Eli Lilly & Co. | 7.095B |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 1.999M |
| EPS Diluted (Quarterly) | -0.0487 |
| Enterprise Value | 5.642M |
| Earnings Yield | -54.34% |
| Normalized Earnings Yield | -54.34 |